2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Pathology, Bioinformatics, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Bispecific Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, ALL, LGL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

3268 AZD3470, a protein arginine methyltransferase 5 (PRMT5) inhibitor, demonstrates robust antitumor activity in preclinical models of MTAP-deficient T-cell lymphoma

Minhui Shen, Brandon Willis, PhD2, Meghana Pandya3, Derek Brandon Oien4, Hyung Joo Lee5, Efthimia R Christoforou6, Stefanie Meyer7, Neeraj Aryal, PhD8, Lanpeng Chen, PhD9, Lauren Bradshaw10, Justine Roderick-Richardson11, Kayleigh Gallagher12, Montira Suksomboon13, Huiyun Liu14, Kaitlyn Beyfuss, MSc15, Connor Hall16, Anas Younes, MD17, Omid Tavana, PhD18, Lisa Drew, PhD19, Jelena Urosevic, PhD20, Cedric Dos Santos, PhD21
1 AstraZeneca, Waltham, Massachusetts, United States
2 AstraZeneca, Waltham, Massachusetts, United States
3 AstraZeneca, Waltham, Massachusetts, United States
4 AstraZeneca, Waltham, Massachusetts, United States
5 AstraZeneca, Waltham, Massachusetts, United States
6 AstraZeneca, Cambridge, United Kingdom
7 AstraZeneca, Waltham, Massachusetts, United States
8 AstraZeneca, Waltham, Massachusetts, United States
9 AstraZeneca, Oss, Netherlands
10 AstraZeneca, Cambridge, United Kingdom
11 AstraZeneca, Waltham, Massachusetts, United States
12 AstraZeneca, Waltham, Massachusetts, United States
13 AstraZeneca, Waltham, Massachusetts, United States
14 AstraZeneca, Waltham, Massachusetts, United States
15 AstraZeneca, Mississauga, Canada
16 AstraZeneca, Waltham, Massachusetts, United States
17 AstraZeneca, NYC, New York, United States
18 AstraZeneca, Waltham, Massachusetts, United States
19 AstraZeneca, Waltham, Massachusetts, United States
20 AstraZeneca, Cambridge, United Kingdom
21 AstraZeneca, Gaithersburg, Maryland, United States

Introduction:

        AZD3470, an MTA-cooperative PRMT5 inhibitor, has shown promising clinical activity and favorable tolerability in the phase 1 PRIMAVERA study in heavily pretreated patients with classical Hodgkin lymphoma(cHL), demonstrating a clear dose-response relationship, with ORR of 58% and CRR of 35% at doses ≥ 450 mg (Derenzini et al., JCO, 2026). Peripheral T-cell lymphomas (PTCLs) are aggressive malignancies with poor clinical outcomes and limited treatment options, representing a significant unmet medical need. MTAP-deficient tumors accumulate methylthioadenosine(MTA), creating a selective vulnerability to MTA-cooperative PRMT5 inhibition. MTAP deficiency has been reported in 45-77% of PTCL cases (Bertino et al., 2012; Maura et al., 2021; Belmontes et al., 2025). DepMap analyses indicate that MTAP expression is frequently altered in T-cell lymphoma (TCL) through copy number loss and/or promoter hypermethylation. Although MTA-cooperative PRMT5 inhibition has shown clinical promise in MTAP-deficient malignancies, its therapeutic potential in TCL has not been systematically evaluated. We therefore investigated the mechanisms of MTAP loss and evaluated the antitumor activity of AZD3470 across multiple preclinical TCL models to assess its potential as a novel targeted therapy for MTAP-deficient PTCL.

Methods:

     MTAP protein expression was assessed by Western blot across a panel of TCL cell lines and compared with MTAP mRNA expression. MTAP promoter methylation was evaluated using methylation-specific ddPCR. AZD3470 sensitivity was evaluated using antiproliferative and cell death assays, and modulation of the PRMT5 downstream biomarker symmetric dimethylarginine (SDMA) was also examined by Western blot following treatment. Antitumor activity and tolerability of AZD3470 were assessed in two MTAP-deficient PTCL xenograft models KARPAS-299 and SU-DHL-1, and in a disseminated MTAP-deficient PTCL patient derived xenograft (PDX) model.

Results: 

         MTAP protein loss was confirmed in 6 of 10 TCL cell lines and was associated with either reduced MTAP mRNA expression or MTAP promoter hypermethylation. Notably, 4 of 6 MTAP-deficient cell lines exhibited MTAP promoter hypermethylation, supporting multiple mechanisms of MTAP silencing in TCL. Consistent with its proposed mechanism of action, AZD3470 demonstrated potent activity in MTAP-deficient TCL models, with GI50 values ranging from 50–500 nM, whereas MTAP-proficient models showed substantially lower sensitivity. Sensitivity was inversely correlated with MTAP expression, with lower MTAP levels associated with greater antiproliferative activity. AZD3470 also induced marked cell death in most MTAP-deficient TCL cell lines. Treatment reduced SDMA levels, confirming inhibition of PRMT5 activity. RNA-sequencing analysis of the MTAP-deficient PTCL cell lines KARPAS-299 and SU-DHL-1 following AZD3470 treatment demonstrated modulation of genes involved in mRNA processing, RNA splicing, and E2F/MYC target programs, consistent with previous observation on cHL (Engstrom et al., 2023). AZD3470 additionally induced alternative splicing events, further supporting on-target activity. In vivo, AZD3470 was well tolerated and induced complete tumor regression in both KARPAS-299 and SU-DHL-1 xenograft models. Complete responses were observed in all mice treated with a clinically relevant dosing regimen of 100 mg/kg twice daily..Pharmacodynamic analyses demonstrated dose-dependent reductions in SDMA, consistent with target engagement in vivo. In an MTAP-deficient disseminated PTCL PDX model, AZD3470 reduced tumor burden by 60% in the femur and 91% in the spleen and prolonged survival, further supporting its antitumor activity in a clinically relevant setting.

Conclusion:

        AZD3470 demonstrated robust in vitro and in vivo antitumor activity in MTAP-deficient TCL models, accompanied by PRMT5 target engagement and pathway inhibition. These findings identify MTAP deficiency as a therapeutic vulnerability in TCL and support the clinical evaluation of AZD3470 in patients with MTAP-deficient PTCL.

Minhui Shen: AstraZeneca - Current equity holder in publicly-traded company; AstraZeneca - Current Employment